Meeting
2019 Genitourinary Cancers Symposium
A phase II study investigating the safety and efficacy of savolitinib and durvalumab in metastatic papillary renal cancer (CALYPSO).
Authors
Thomas Powles
Barts Cancer Institute, Royal Free NHS trust, St. Bartholomew’s Hospital, London, United Kingdom
Thomas Powles , James M. G. Larkin , Poulam Patel , Begoña Pérez-Valderrama , Alejo Rodriguez-Vida , Hilary Glen , Fiona Thistlethwaite , Christy Ralph , Gopalakrishnan Srinivasan , Maria Jose Mendez-Vidal , Wing-Kin Liu , Aaron Prendergast , Laura Vosper , Kelly Mousa , Cristina Suárez
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session C: Renal Cell Cancer
Track
Renal Cell Cancer
Sub Track
Renal Cell Cancer
Clinical Trial Registration Number
NCT02819596
Citation
J Clin Oncol 37, 2019 (suppl 7S; abstr 545)
DOI
10.1200/JCO.2019.37.7_suppl.545
Abstract #
545
Poster Bd #
D6
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Annual Meeting
Clinical activity of durvalumab and savolitinib in MET-driven, metastatic papillary renal cancer.
First Author: Cristina Suarez Rodriguez
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Efficacy and safety of nivolumab and CapeOX in patients with previously untreated FGFR2-positive, PD-L1-positive advanced gastric cancer: A single-arm, multicenter, phase 2 study NIVOFGFR2.
First Author: Ilya Tsimafeyeu
First Author: Francesca Jackson-Spence
Poster
2018 ASCO Annual Meeting
A phase 2 study to assess the efficacy and safety of autologous tumor-infiltrating lymphocytes (TIL, LN-145) alone and in combination with anti-PD-L1 inhibitor durvalumab in patients with locally advanced or metastatic NSCLC.
First Author: Sylvia Mina Lee